drugset / Trial / NCT04387773
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Phase 4
Completed
8 enrolled
Oregon Health and Science University
Adamas Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended release) on activity levels and measures of gait and balance quality in people with Parkinson's disease (PD) and levodopa induced dyskinesia (LID) during daily activities using body-worn sensors.
Timeline
- Start
- 2020-11-05
- Primary completion
- 2022-09-01
- Completion
- 2022-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amantadine | Unknown | 274 mg | — |